Perceptions of drug costs may affect how much patients benefit from the drug, according to a study treating participants with a placebo. The results were published in the online issue of Neurology.
Perceptions of drug costs may affect how much patients benefit from the drug, according to a study treating participants with a placebo. The results were published in the online issue of Neurology.
In the study “Placebo effect of medication cost in Parkinson disease: A randomized double-blind study” from Alberto J. Espay, MD, MSc, of the University of Cincinnati in Ohio and a fellow of the American Academy of Neurology, and colleagues studied 12 patients with moderate to severe Parkinson disease and motor fluctuations. The patients were randomized to a “cheap” or “expensive” placebo. After 4 hours, they were crossed over the alternate arm.
"Patients' expectations play an important role in the effectiveness of their treatments, and the placebo effect has been well documented, especially in people with Parkinson's disease," Dr Espay said in a statement. "We wanted to see if the people's perceptions of the cost of the drug they received would affect the placebo response."
The participants were told the shots they were receiving were 2 formulations of the same drug that were believed to be of similar effectiveness, but that one cost $100 per dose and the other cost $1500 per dose. They were told the purpose of the study was to prove the drugs were equally effective despite their different price tags.
Both placebos improved motor function, but the benefit was greater when patients were randomized first to the expensive placebo. While the effect of the expensive placebo was less than levodopa, the placebo did significantly improve motor function and decrease brain activation.
After the participants were told the true purpose of the study.
"Eight of the participants said they did have greater expectations of the ‘expensive’ drug and were amazed at the extent of the difference brought about by their expectations," Dr Espay said. "Interestingly, the other 4 participants said they had no expectation of greater benefits of the more expensive drug, and they also showed little overall changes."
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More